Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Tolerion

131 Oyster Point Boulevard Suite 400
South San Francisco, CA 94080
USA
415-795-5800
Website Company Summary Management Team
Management

General Management: Alexander Fleming
Finance: James Stutz (6/30/2019)
Technology: Graeme Currie (12/31/2019)
Board

Outside board: (May no longer be on the board) Stephen Zachary (Sands Capital Principal) Paul Manning (PBM Capital Group CEO/President) Sean Stalfort (PBM Capital Group Principal) Lawrence Steinman (Stanford University School of Medicine)
Company

Business description: Tolerion is a clinical-stage biopharmaceutical company with a product portfolio built around our novel antigen-specific immune tolerance induction platform. Our first three named product candidates, one in late stage clinical trials, address autoimmune disorders with candidates invented with our proprietary platform. We engineer product candidates that restore balance in autoimmune conditions in which self-antigens (or “autoantigens”) incite a destructive immune response. This approach has the important benefits of targeting the root of the pathogenic immune response without impairing healthy immune function more broadly. This affords significant efficacy and safety advantages relative to other approaches in development.
Partners include: Genentech ;  Juvenile Diabetes Research Foundation
Capital

Rounds: 4
Recent Fundings: Jan 2020   Dec 2008
Capital raised: 137.0M
Last Round: 20.0M
Ownership: Private   Ipo Filing
VCs include: Presidio PartnersU.S. Venture PartnersMorgenthaler VenturesLatterell Venture Partners;  Vertical Ventures;  A.M. PappasAndAssociates;  CIDC Consultants;  Montreux Equity Partners;  Grand Cathay Venture Capital Company;  Prudence Venture Investment Corp;  Quintiles PharmaBio Development;  Boston Life Science Venture Corp;  PAC-LINK Bio Management Corp;  unnamed investors
Corporate investors: Lilly Ventures

Last Tweets


 

Last Mentions


Overview
Record updated: Sep 2020
Sector: Biotech
Year Founded: 2001
Headcount: 26-50 as of Jan 2008
Rounds: 4
Recent Fundings: Jan 2020   Dec 2008
Capital Raised: 137.0M
Last Round: 20.0M
Ownership: Private   Ipo Filing